Company intelligence / Profile preview

K2 VBI Equity Trust

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

VBI's platforms have resulted in commercial approval for a hepatitis B vaccine and clinical-stage programs in cytomegalovirus and glioblastoma. PreHevbrio™, VBI's 3-antigen hepatitis B vaccine, is approved in multiple countries but was recalled due to the bankruptcy and operational shutdown of VBI Vaccines Inc. in late 2024.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinemRNA-based drugsRecombinant proteinVirus-like particle
Industry: Biotech

Partnerships

K2 HealthVentures (investment/debt finance provider prior to acquisition)

Beyond the preview

Go deeper on K2 VBI Equity Trust.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K2 VBI Equity Trust.

Explore the full profile